VSTM, US92337C2035

Verastem announces KRAS data and CEO transition for Verastem stock

Published on 10/15/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Verastem reports a 50.00 percent response rate in pancreatic cancer. Verastem stock costs EUR 7.39 on October 15, 2026.

Clinical data and leadership change

Verastem reported a 50.00 percent response rate in second-line pancreatic cancer on October 14, 2026.
The company priced a USD 250.0 million offering on October 14, 2026.
Verastem stock was trading at EUR 7.39 at 1:17 p.m. CEST at Lang & Schwarz on October 15, 2026.

VSTM, US92337C2035, Illustration mit AI erstellt.

Verastem (ISIN US92337C2035) reported a 50.00 percent confirmed objective response rate for VS-7375 in second-line metastatic pancreatic cancer on October 14, 2026. The update also included a planned chief executive transition and a USD 250.0 million stock offering, according to Verastem.

VS-7375 delivers measurable responses

The 900-milligram dose produced confirmed responses in 4 of 8 patients treated in the second-line setting. Across second-line and later pancreatic treatment, the confirmed response rate was 41.00 percent among 22 patients, including two complete responses, one confirmed and one unconfirmed, based on the October 7, 2026 data cutoff.

Verastem is advancing VS-7375, an investigational oral KRAS G12D inhibitor, into a planned first-line pancreatic cancer Phase 3 study. The company said the study is expected to begin by the end of 2026, while the broader TARGET-D program also covers colorectal and non-small cell lung cancers.

What does the funding mean?

The company priced 30,937,500 common shares at USD 8.00 each together with 312,503 pre-funded warrants. Gross proceeds are expected to reach USD 250.0 million before underwriting discounts and expenses, with the funds intended for VS-7375 development and working capital, according to Verastem. The offering is expected to close on October 15, 2026.

Leadership dates are set

Michael P. Bailey is scheduled to become president and chief executive officer on January 1, 2027, succeeding Daniel Paterson, who plans to retire from the role. Verastem said the transition follows the rapid development of VS-7375 toward late-stage testing.

Stock indication in euros

The stock was trading at EUR 7.39 at Lang & Schwarz on October 15, 2026 at 1:17 p.m. CEST. The company is listed on Nasdaq under VSTM and focuses on medicines for cancers driven by RAS/MAPK pathway alterations.

The further course of trading is shown by the continuously updated real-time quote of Verastem stock.